Liquid Biopsy Results Could Guide, Expedite Clinical Trial Enrollment
Researchers assessed the use of cfDNA-based liquid biopsy to guide and expedite clinical trial enrollment for patients with with metastatic urothelial carcinoma.
Diagnosis & Disease Information
Cardiotoxicity Risk Greater in Blacks With Breast Cancer Receiving HER2 Therapies
Retrospective study examines the association between risk of cardiotoxicity and race in women with breast cancer receiving chemotherapy and at least 1 year of HER2-targeted therapy.
Emerging Treatments for HER2-positive Early-stage Breast Cancer: Focus on Neratinib
[OncoTargets and Therapy] This research reviews available data on the role of the HER2 pathway in breast cancer and on the different targeted agents for the treatment of patients with early-stage HER2-positive disease, with a particular focus on neratinib.
A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
CDK4/6 inhibitors, which block the activity of regulatory enzymes, are tolerated fairly well in patients with cancer; however, oncology nurses should be aware of some strategies that minimize their adverse effects.
Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review
In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.
First Case of Dermatomyositis Associated with Secondary Myelofibrosis Following Polycythemia Vera
A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.
Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
Phase 3 clinical trial results show fewer adverse effects and longer survival with alectinib compared with crizotinib in patients with treatment-naïve ALK-positive NSCLC.
Spherical Shape of New Drug Holds Promise for Bypassing the Blood Brain Barrier and Treating Aggressive Brain Cancer
An investigational drug with a novel spherical nucleic acid structure has the potential to cross the blood-brain barrier to treat glioblastoma multiforme.
No Improvement in KRAS-Mutation Lung Cancer With MEK Inhibitor Plus Chemotherapy
A combination treatment of mitogen-activated protein kinase MEK inhibitor and chemotherapy did not improve progression-free survival in patients with advanced lung cancer caused by a KRAS gene mutation.
PAD4 Inhibition Repairs, Reverses Cancer Tumor-Induced Kidney Damage
A potential treatment targeting neutrophils holds promise for limiting kidney damage and improving renal function in cancer.
- Loading...
Loading...
Next post in Side-Effect Management
Loading... 
Loading...